Effects of high-flow nasal cannula in patients with persistent hypercapnia after an acute COPD exacerbation: a prospective pilot study

Lara Pisani 1*, Sara Betti 2,3, Carlotta Biglia 2,3, Luca Fasano 1, Vito Catalanotti 2,3, Irene Prediletto 2,3, Vittoria Comellini 1, Letizia Bacchi-Reggiani 4 and Stefano Nava FERS 2,3

Abstract

Background: Persistent hypercapnia after COPD exacerbation is associated with excess mortality and early rehospitalization. High Flow Nasal cannula (HFNC), may be theoretically an alternative to long-term noninvasive ventilation (NIV), since physiological studies have shown a reduction in PaCO2 level after few hours of treatment. In this clinical study we assessed the acceptability of HFNC and its effectiveness in reducing the level of PaCO2 in patients recovering from an Acute Hypercapnic Respiratory Failure (AHRF) episode. We also hypothesized that the response in CO2 clearance is dependent on baseline level of hypercapnia.

Methods: Fifty COPD patients recovering from an acute exacerbation and with persistent hypercapnia, despite having attained a stable pH (i.e. pH > 7.35 and PaCO2 > 45 mmHg on 3 consecutive measurements), were enrolled and treated with HFNC for at least 8 h/day and during the nighttime.

Results: HFNC was well tolerated with a global tolerance score of 4.0 ± 0.9. When patients were separated into groups with or without COPD/OSA overlap syndrome, the “pure” COPD patients showed a statistically significant response in terms of PaCO2 decrease (p = 0.044). In addition, the subset of patients with a lower pH at enrolment were those who responded best in terms of CO2 clearance (score test for trend of odds, p = 0.0038).

Conclusions: HFNC is able to significantly decrease the level of PaCO2 after 72 h only in “pure” COPD patients, recovering from AHRF. No effects in terms of CO2 reduction were found in those with overlap syndrome. The present findings will help guide selection of the best target population and allow a sample size calculation for future long-term randomized control trials of HFNC vs NIV.

Trial registration: This study is registered with www.clinicaltrials.gov with identifier number NCT03759457.

Keywords: Chronic obstructive pulmonary disease, High flow nasal cannula, Persistent hypercapnia, Long term non invasive ventilation.

© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

A number of observational studies have reported increased mortality associated with chronic hypercapnia in patients with Chronic Obstructive Pulmonary Disease (COPD) [1, 2]. For this reason, long-term noninvasive ventilation (NIV) has been suggested as a strategy to decrease the PaCO2 levels, with a few investigations demonstrating an improvement in survival and/or exacerbation rates [3–5].

High levels of inspiratory pressure are usually applied in an attempt to maximally reduce PaCO2 [4, 5], but this approach may be not well tolerated in all the patients.

An alternative method to reduce hypercapnia is the use of high flow nasal cannula (HFNC). Physiological short term studies have shown that HFNC can generate an acute reduction of PaCO2 [6–8], even over a wide variation of different baseline PaCO2 levels (from as low as 1.3 mmHg for a PaCO2 of 38.4 mmHg (−3%) to 6.4 mmHg for a PaCO2 of 61.2 mmHg (−9.2%). When compared to NIV, HFNC also demonstrated a similar reduction of inspiratory muscle effort, compared to spontaneous breathing [7].

HFNC therapy is reported to improve patient comfort [9–12], avoid mucosal dryness and injury [13–15], and deliver a more reliable and stable fraction of inspired oxygen (FiO2) [13, 16].

One investigation with 11 COPD patients [17] treated for 6 weeks of home HFNC, showed a significant and impressive reduction in PaCO2 compared to baseline (> 8 mmHg). However, this study had a small sample size, relied on the recording of arterialized PaCO2 measurements, and used a relatively low fixed flow of 20 L/min, that has been shown to have a lower CO2 clearance than studies using higher flow rates [17].

A randomized cross-over study in stable hypercapnic COPD patients on long-term oxygen therapy (LTOT) demonstrated that the addition of HFNC was able to improve health-related Quality of Life (QoL) and reduce hypercapnia in these patients [18]. However, the participants in this trial were atypical of most patients with severe COPD, since 37% were stage GOLD II and III and had comparatively low exacerbation and hospital admission rates, which may limit the clinical applicability of these findings [18]. Recently, it has been demonstrated that HFNC treatment reduced acute exacerbations, hospital admissions and symptoms in COPD patients with hypoxic failure [19]. This highlights the need for future randomised trials comparing HFNC vs NIV.

In fact, for patients with persistent hypercapnia following an acute life-threatening exacerbation of COPD, Murphy et al. [5] showed that the addition of home NIV to home oxygen therapy prolonged the time to readmission or death over a 12-month period.

In the current investigation, the goal was to assess the acceptability of HFNC and its effectiveness in reducing the level of PaCO2. The longer term research goal, based on previous physiological studies, is to demonstrate that the response of COPD patients with persistent hypercapnia after an acute exacerbation to HFNC is dependent on their baseline level of hypercapnia. This current study will help guide selection of the best target population and allow a sample size calculation for future long-term randomized control trials (RCTs) of HFNC vs NIV.

METHODS

Fifty COPD patients recovering from an acute exacerbation requiring hospital admission and with persistent hypercapnia, despite having attained a stable pH (i.e. pH > 7.35 and PaCO2 > 45 mmHg on 3 consecutive measurements), were enrolled in this interventional study. The protocol was approved by our local ethical committee and written informed consent was obtained from each patient. This study is registered with www.clinicaltrials.gov with identifier number NCT03759457.

Documented or highly suspected OSA/COPD overlap syndrome was not considered an exclusion criteria and was defined as the presence of 15 or more obstructive respiratory events per hour of sleep, when a previous full night polysomnography (PSG) was available (n.12 patients) [20] or from a positive Epworth questionnaire and a Body Mass Index (BMI) > 25 (n.11 patients) [21].

Cardiac decompensation, restrictive thoracic disorders, renal insufficiency, cancer, and neurological disease were considered exclusion criteria.

On day 1 the patients underwent a preliminary trial with HFNC to set the optimal flow, using the AIRVO 2 (Fisher & Paykel Healthcare, Auckland, New Zealand). The patients were asked to breathe while trying to keep their mouth closed at flow rates from 20 L/min up to 40 L/min for a minimum of 15 min, if tolerated, for each trial. At the end of this test, the maximum level tolerated for 15 min was chosen as the flow to be used for the experimental procedure. Temperature was set according to the patient’s tolerance starting from 31 °C, up to 37 °C, while FiO2 was adjusted to maintain an SaO2 between 92 and 94%.

Between 9 am of day 2 and 9 am of day 5 (72 h period), patients underwent HFNC for at least 8 h/day plus during the nighttime. The nurse on shift was in charge of supervising the adherence to this schedule and to record any protocol violations on a dedicated sheet. Recorded every morning at 10 am were: Arterial Blood Gases (ABGs) performed without violations on a dedicated sheet. Recorded every morning at 10 am were: Arterial Blood Gases (ABGs) performed without HFNC, effective hours of HFNC and therapy tolerance, as measured through patient self-reporting using the following scale: 1. very bad, 2. bad, 3. moderate, 4. good, and 5. very good.

Statistical analysis

Data are presented as a mean and standard deviation (SD). We used Repeated Measures Analysis of Variance to analyse the ABGs changes and the tolerance to HFNC during the trial. Repeated Measures Analysis of Variance were used to determine the difference between overlap
syndrome COPD patients and “pure” COPD patients, without overlap syndrome. Post-hoc pairwise comparisons were performed with pairwise Bonferroni’s method. A test for linear trend of the odds was used to compare the baseline PaCO2 levels against the changes in PaCO2 after 48 h and pH values at baseline.

We considered two-sided p values less than 0.05 to be statistically significant. Statistical analysis was performed with Stata/Se 14.2 software (StataCorp, College Station TX, USA).

**Results**

Table 1 shows the clinical characteristics of the patients. None of the patients were on a home care ventilator program, either due to having previously refused NIV or because they did not meet the enrollment criteria established in our unit (i.e. PaCO2 > 55 mmHg). All were naive to HFNC therapy. 12/50 patients were affected by overlap syndrome.

The protocol was well tolerated by all but one of the patients without major discomfort or any change in the time course of the experiment with regards to flow, temperature and FiO2. The mean flow applied was 33.5 ± 3.2 L/min. The exception was one patient found the warm temperature uncomfortable. HFNC was well tolerated with a global tolerance score of 4.0 ± 0.9. The mean usage of HFNC was 64.5 ± 10.5 h.

Overall, 70% of patients (35/50) received NIV prior to HFNC, most of these patients were “pure” COPD (25/35). Table 2 shows key patient characteristics according to blood gases during exacerbation and the time interval between treatments.

Figure 1 is a plot of the time course of PaCO2 during the trial. Although a positive trend of PaCO2 reduction was observed, no significant differences were found among the trial in all patients. However, a statistically significant reduction in respiratory rate was observed at 48 h (Fig. 2).

Table 3 summarizes the ABG values; no statistically significant differences were found in terms of pH, HCO3− and PaO2/FiO2 ratio changes during the trial. On the other hand, when the patients were separated into groups with or without COPD/OSA overlap syndrome, the “pure” COPD patients showed a statistically significant response in terms of PaCO2 decrease (p = 0.044). The comparison of trends of PaCO2 among COPD patients and subjects with overlap syndrome is shown in Fig. 3.

The patients were divided into two groups: those for whom a reduction of PaCO2 from baseline to 48 h occurred (Group A) and those for whom PaCO2 either increased or changed “minimally” (−2%) (Group B). When comparing the two groups, it was found that patients with a lower pH were more likely to respond to HFNC (Fig. 4, Table 4, score test for trend of odds, p = 0.0038).

**Discussion**

In this study performed in patients with persistent hypercapnia after an episode of AHRF, we have shown for the first time that while HFNC is able to significantly decrease the level of PaCO2 after 72 h in “pure” COPD patients, this was not the case for those with overlap syndrome. In addition, the subset of patients with a lower pH at enrolment were those who responded best in terms of CO2 clearance. This study highlights the need for an RCT comparing the long term effects of NIV vs HFNC, in the cluster of patients more likely to respond to HFNC.
Several short-term physiological studies (a maximum of 2 h total test time) [6, 7] have shown that HFNC can improve some relevant physiological parameters, including decreasing the level of hypercapnia, in stable COPD patients. A randomized controlled study comparing HFNC with “standard” oxygen demonstrated that the former was able to significantly reduce PaCO$_2$, while improving quality of life [18].

Recently, Storgaard and colleagues [19] in a large sized study randomized 200 COPD patients with chronic hypoxic respiratory failure to long term oxygen therapy (LTOT) or LTOT plus HFNC home treatment for 12 months. This study showed that the long-term HFNC treatment significantly reduces acute exacerbations, hospitalization and PaCO$_2$ levels, therefore suggesting that HFNC may be an alternative to home NIV for some COPD patients [19].
As the physiological mechanisms of NIV and HFNC treatments are quite different, it is important to better understand which subset of patients are more likely to benefit from HFNC long-term application.

For example, NIV is likely to correct the mechanism leading to hypercapnia through increasing alveolar ventilation, by augmenting tidal volume while reducing respiratory rate, and reducing CO₂ production by decreasing the work of breathing [22–24]. HFNC on the other hand may also increase tidal volume and reduce the inspiratory effort [6–8], although to a lesser extent than NIV [7], but may have additional physiological mechanisms [25].

For example, HFNC improves the lung mucociliary clearance [13–15], the washout of upper airway dead space [26–29], and generates a low level of positive airway pressure (PEEP effect) [16, 30–32], together with a decrease in inspiratory resistance and an increase in expiratory resistance [13, 33].

NIV has been suggested to decrease the number of exacerbations per year and also mortality in two different groups of COPD patients, either in a phase of clinical stability or with persistent hypercapnia after an episode of AHRF [5]. The approach used in the second patient group was probably reported to be more “accepted” and tolerated, since the drop out and non-compliant rate was about 40% in the patients enrolled when already stable vs 10% of those enrolled a few days after the hospital discharge [5].

For this reason, we decided to study the effect of HFNC in the latter cluster of patients.

We have shown for the first time that patients with a combination of COPD and sleep apnea (i.e. overlap syndrome) are not likely to benefit from HFNC treatment. Most of the previous clinical and physiological studies did not exclude a priori these subjects.

Few investigations assessed the effects of HFNC during sleep, showing that while breathing pattern response to HFNC depends on the wake/sleep state in normal healthy adults, it varies widely during wakefulness in patients with COPD [34, 35].

Indeed it was shown that during sleep these patients have a more rapid shallow breathing pattern using HFNC, compared with that of the control group on standard oxygen, but on the other hand they decreased PaCO₂, as well as Work of Breathing, indicating a better alveolar ventilation [34, 35].

The authors of the latter study concluded that HFNC may be used during sleep as an alternative means to assist ventilation in patients prone to develop respiratory failure due to increased respiratory loads or insufficient alveolar ventilation [34].

Unfortunately, the patients enrolled were not likely to be affected by sleep disturbancies, as demonstrated by the low Respiratory Disturbance Index (RDI) and by the absence of relevant desaturations [34].

Despite the favourable results of the Biselli study [34], it is likely, as demonstrated in our study, that the effects of HFNC are not sufficient in overlap syndrome patients to fully relieve the increased mechanical load imposed by hyperinflation on poorly functioning respiratory muscles. NIV normalizes nocturnal hypoxemia, enhances the

| Table 3 | ABG values during the trial |
|---------|-----------------------------|
|         | baseline | 24 h  | 48 h  | 72 h  |
| pH      | 7.41 ± 0.006 | 7.42 ± 0.006 | 7.42 ± 0.006 | 7.43 ± 0.007 |
| PaCO₂ (mmHg) | 60 ± 1.41 | 59.7 ± 1.43 | 59.4 ± 1.46 | 56.7 ± 1.7 |
| PaO₂/FiO₂ | 200.5 ± 61 | 196.4 ± 58 | 208 ± 63 | 200.2 ± 66 |
| HCO₃⁻ (mmol/L) | 35.3 ± 1.03 | 36.7 ± 1.04 | 36.6 ± 1.06 | 35.3 ± 1.2 |

Data are presented as mean ± SD

Fig. 3 Trend of PaCO₂ values during the trial according the presence or not of COPD/OSA overlap syndrome. *72 h vs baseline: \( p = 0.044\) (Bonferroni-adjusted \( p \)-values)
quality of sleep, and may even restore the hyporesponsiveness to CO₂ [36, 37]. In addition, treatment with continuous positive airway pressure (CPAP) significantly reduces mortality and severe COPD exacerbations leading to hospitalization that have been shown to occur in these patients [38].

The present study largely confirms the data obtained with COPD patients with a pH in the normal range, whether clinically stable or recovering from an AHRF episode, showing that HFNC may be efficient in reducing PaCO₂ and respiratory rate [6, 7, 17, 18].

In patients with hypercapnic respiratory failure, HFNC use for 6 weeks led to a decrease in capillary pCO₂ [17] and similar results were obtained in a short term study showing not only a reduction in PaCO₂ but also in oxygen consumption [39].

Similar changes in PaCO₂ were described in another investigation where HFNC led to a flow-dependent reduction in PaCO₂, with values becoming close to normocapnia, accompanied by an increase in Tidal Volume (TV) and a decrease in minute volume, resulting in a reduction of the rapid shallow breathing index, an indicator of respiratory work load [40].

In patients with hypercapnic respiratory failure, HFNC use for 6 weeks led to a decrease in capillary pCO₂ [17] and similar results were obtained in a short term study showing not only a reduction in PaCO₂ but also in oxygen consumption [39].

In a second similar study, Pisani et al. [7] studied the effects of HFNC versus NIV on inspiratory effort in fourteen patients with hypercapnic COPD, by measuring transdiaphragmatic pressure, breathing pattern and gas exchange. HFNC and NIV were both able to significantly improve breathing pattern and reduce inspiratory effort when compared to standard oxygen; however, arterial carbon dioxide oxygen tension decreased, but not

Table 4 Score test for trend of odds between Groups A and B according to ranges of pH values

| pH ranges | Group B | Group A | Odds   | (95% Conf. Interval) |
|-----------|---------|---------|--------|---------------------|
| 7.35–7.37 | 3       | 7       | 0.42857| 0.11083 -1.65733   |
| 7.38–7.39 | 1       | 5       | 0.20000| 0.02337 - 1.71188  |
| 7.40–7.41 | 4       | 6       | 0.66667| 0.18813 - 2.36242  |
| 7.42–7.43 | 6       | 3       | 2.00000| 0.50020 -7.99688   |
| 7.44–7.45 | 4       | 1       | 4.00000| 0.44708 -35.78757  |
| ≥7.46     | 7       | 2       | 3.50000| 0.72709 -16.84797  |

Score test for trend of odds: p = 0.0038

Patients were divided into two groups: those for whom a reduction of PaCO₂ from baseline to 48 h occurred (Group A) and those for whom PaCO₂ either increased or changed “minimally” (−2%) (Group B). This table shows the Score test for trend of odds between the two groups according to ranges of pH values.
significantly [7]. Several mechanisms are involved in the explanation of these results [7, 25], such as the reduction of inspiratory resistance and anatomical dead space in the upper airways as well as the down-regulation of cold receptors or osmoreceptors in the nasal mucosa. The prolonged expiratory time may also reduce the amount of PEEPi, which may be the source of increased inspiratory load, while increasing the end-expiratory and tidal volumes, and decrease the respiratory rate [7, 25].

This study therefore highlights the potential of using HFNC as alternative to NIV in COPD patient with chronic hypercapnic patients.

The “exact” moment to start NIV in these patients is, however, still controversial. In Köhnelin’s study [4] NIV was initiated a relatively long time after an acute episode of exacerbation, but despite the favourable results, the drop out and/or compliance rate was suboptimal, while in another RCT [5], showing similar results, NIV was started after an episode of AHRF requiring NIV treatment and the compliance rate was much better overall.

As already stated, all the studies using HFNC were performed a relatively long time after an episode of AHRF, and in patients not very likely to be ideal candidates for long-term NIV, because of the level of hypercapnia, their severity stage and the number of previous exacerbations. Therefore these results should not be considered when designing a RCT, with a head-to-head comparison between NIV and HFNC in patients likely to benefit more from long term NIV.

Interestingly enough our results also showed that in this subset of patients, the greatest PaCO2 reduction was observed mainly in patients with lower pH, despite being in the normal range.

Our study has some limitations. First of all, not all the patients with overlap syndrome performed a full night polysomnography, but obviously their medical history, BMI and Epworth questionnaire suggested a likely combination between COPD and sleep apnea syndrome. Secondly, one may argue that the mean flow rate applied (33 L/min), may be suboptimal to obtain a maximized CO2 clearance [41]. However, the flow employed in this study was based on the patient’s tolerance, which is the key to success when proposing a long-term chronic application.

Finally, the study was performed in the recovery phase of acute COPD exacerbation, that means the patients might be still in the process of PaCO2 reduction, especially in the subset of patients with a lower pH at enrolment [42]. Therefore, it is difficult to attribute the CO2 reducing effect to HFNC alone without a control group. However, the hypothesis tested in this study is still legitimate as the fact that home NIV and long term oxygen therapy (LTOT) has less physiological and clinical effect in patients with the reversible hypercapnic phenotype [42, 43]. In addition, in this “proof of concept” study, we wanted to show that HFNC is able to reduce PaCO2 not only in the stable phase, as already shown, but also after an acute exacerbation, that is nowadays the “ideal” target for starting home NIV, as suggested by the recent European Respiratory Society guidelines on long-term home non-invasive ventilation [44].

Conclusions
In conclusion we have shown that in COPD patients recovering from an episode of AHRF, which have reached a normal pH, the use of HFNC was associated with a statistically significant reduction in PaCO2 and respiratory rate. The better response was obtained in the subset of individuals with a lower pH level. This was not the case for COPD patients with the overlap syndrome. The results of this study may be useful to determine the sample size and the “ideal” characteristics of patients to include in an RCT aimed at assessing the efficacy of HFNC vs NIV in COPD patients recovering from an episode of AHRF.

Acknowledgements
Not applicable

Authors’ contributions
Data collection, writing and design the study: L.P. Data collection and data management: S.B., C.B. Data collection: V.C1, V.C2. Statistical analysis and writing: L.B.R, I.P. Study design and writing: L.F. Data review, study design and writing: S.N. All Authors read and approved the final version of the manuscript.

Funding
No funding was received.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The protocol was approved by our local ethical committee (Comitato Etico di Area Vasta Emilia Centro della Regione Emilia Romagna, CE -AVEC), reference number CE249/2018/Oss/AOUBo. Written informed consent was obtained from each patient.

Consent for publication
Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient/parent/guardian/relative of the patient. A copy of the consent form is available for review by the Editor of this journal.

Competing interests
Dr. Lara Pisani received travel expense reimbursement from Fisher & Paykel
Dr. Lara Pisani is also an Associate Editor with the BMC Series.

Abbreviations
ABGs: Arterial Blood Gases; AHRF: Acute Hypercapnic Respiratory Failure; BMI: Body mass index; CO2: Carbon dioxide; COPD: Chronic Obstructive Pulmonary Disease; FiO2: Fraction of inspired oxygen; GOLD: The Global Initiative for Chronic Obstructive Lung Disease; HFNC: High Flow Nasal Cannula; LTOT: Long-term oxygen therapy; NIV: Noninvasive ventilation; OSA: Obstructive sleep apnea; PaCO2: Arterial partial pressure of carbon dioxide; PEEP: Positive end-expiratory pressure; PEEPi: Intrinsic positive end-expiratory pressure; PSG: Polysomnography; QoL: Health-related Quality of Life; RCT: Randomized controlled trial; RDI: Respiratory Disturbance Index; SaO2: Oxygen saturation; SD: Standard deviation; TV: Tidal Volume
Hasani A, Chapman TH, McCool D, Smith RE, Dilworth JP, Agnew JE. Evaluation of humidified nasal high flow oxygen system, using oxygen, capnography and measurement of upper airways pressure. Anesth Intensive Care. 2013;39(6):1103–10.

Ritchie JE, Williams AB, Gerard C, Hockey H. Evaluation of humidified nasal high flow oxygen system, using oxygen, capnography and measurement of upper airways pressure. Anesth Intensive Care. 2011;39(5):1103–10.

Bräunlich J, Seyfath HJ, Wirtz H. Nasal high-flow versus non-invasive ventilation in stable hypercapnic COPD: a preliminary report. Multidiscip Respir Med. 2015;10(1):27.

Nagata K, Kikuchi T, Horie T, Shiraki A, Kitajima T, Kadowaki T, et al. High-flow nasal cannula oxygen therapy for patients with stable Hypercapnic chronic obstructive pulmonary disease. A multicenter randomized crossover trial. Ann Thorac Soc. 2018;13(4):432–9.

Storgaard LH, Hockley HU, Laursen BS, Weinreich UM. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstr Pulmon Dis. 2018;13:195–205.

Wang Y, Hu K, Liu K, Li Z, Yang J, Dong Y, Nie M, Chen J, Ruan Y, Kang J. Obstructive sleep apnea exacerbates airway inflammation in patients with chronic obstructive pulmonary disease. Sleep Med. 2015;16:1123–30.

Schreiber A, Gemmi F, Ambrosino N, Ceriana P, Lastoria C, Carlacci U. Prevalence and predictors of obstructive sleep apnea in patients with chronic obstructive pulmonary disease undergoing inpatient pulmonary rehabilitation. COPD. 2018;15:265–70.

Diaz O, Iglesia R, Ferrer M, Zavala E, Santos C, Wagner PD, et al. Effects of noninvasive ventilation on pulmonary gas exchange and hemodynamics during acute hypercapnic exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;156:1840–5.

Appendini L, Patessio A, Zanoboni S, Carone M, Gokul B, Donner CF, Rossi A. Physiologic effects of post-expiratory pressure and mask pressure support during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;149:1069–76.

Biselli P, Fricke K, Grote L, Schulz A, Stumpf A, Shaffer TH, Dysta K. High-flow nasal cannula: impact on oxygenation and ventilation in an acute lung injury model. Pediatr Pulmonol. 2011;46:67–74.

Müller W, Celik G, Feng S, Bartenstein P, Meyer C, Olbrich S, Schmid O, Tatsk T. Nasal high flow clears anatomical dead space in upper airway models. J Appl Physiol. 2015;118:255–32.

Bräunlich J, Wirtz H. Nasal Highflow (NHF) reduces PCO2 in a sheep lung model via airway wash-out. Pneumologie. 2016;70:710.

Bräunlich J, Muenzburger F, Wirtz H. Effectiveness of nasal highflow in hypercapnic COPD patients is flow and leakage dependent. BMC Pulm Med. 2018;18:14.

Goves N, Tobin A. High flow nasal oxygen generates positive airway pressure in adult volunteers. AAF. J. 2007;2012:26–31.

Parke RL, McGuinness SP. Pressures delivered by nasal high-flow oxygen during all phases of the respiratory cycle. Respir Care. 2013;58:1621–4.

Parke RL, Eccleston ML, McGuinness SP. The effects of flow on airway pressure during nasal high-flow oxygen therapy. Respir Care. 2011;56:1151–5.

Mundell T, Feng S, Tatkov S, Schneider H. Mechanisms of nasal high flow ventilation during wakefulness and sleep. J Appl Physiol. 2013;114:1058–65.

Biselli PJ, Kirkness JP, Grote L, Fricke K, Schwartz AR, Smith P, Schneider H. Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls: a prospective observational study. J Appl Physiol (1985). 2017;121(2):82–8.

Biselli P, Fricke K, Grote L, Braun AT, Kirkness J, Schneider H. Reductions in dead space ventilation with nasal high flow flow depend on physiological dead space volume: metabolic hood measurements during sleep in patients with COPD and controls. Eur Respir J. 2018;51:170251. https://doi.org/10.1183/13993003.0251-2017.

Vitacca M, Nava S, Confalonieri M, Bianchi L, Porta R, Cini E, Ambrosino N. The appropriate setting of noninvasive pressure support ventilation in stable COPD patients. Chest. 2000;118:286–93.

Fanfulla F, Delmastro M, Berardini E, Lupo ND, Nava S. Effects of different ventilator settings on sleep and inspiratory effort in patients with neuromuscular disease. Am J Respir Crit Care Med. 2005;172:2619–24.

Marin JM, Soriano JB, Carrozzi SJ, Boldova A, Celli BR. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med. 2010;182(3):325–31.
39. Vogelsinger H, Halank M, Braun S, Wilkens H, Geiser T, Ott S, Stucki A, Kaehler CM. Efficacy and safety of nasal high-flow oxygen in COPD patients. BMC Pulm Med. 2017;17:143.

40. Bräunlich J, Köhler M, Wirtz H. Nasal highflow improves ventilation in patients with COPD. Int J COPD. 2016;11:1077–85.

41. McKinstry S, Pilcher J, Bardsley G, Berry J, Van de Hei S, Braithwaite J, et al. Nasal high flow therapy and PtCO2 in stable COPD: a randomized controlled cross-over trial. Respirology. 2018;23(4):378–84.

42. Struik FM, Sprooten RT, Kerstjens HA, Bladder G, Zijnen M, Asin J, et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax. 2014;69:826–34.

43. Murphy PB, Hart N. Home non-invasive ventilation for COPD: how, who and when? Arch Bronconeumol. 2018;54(3):149–54.

44. Ergen B, Oczkowski S, Rochwerg B, Cafucci A, Chatwin M, Clini E, et al. European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. Eur Respir J. 2019;54(3). https://doi.org/10.1183/13993003.01003-2019.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.